EGFR-induced phosphorylation of type Iγ phosphatidylinositol phosphate kinase promotes pancreatic cancer progression
Metrics: PDF 1143 views | HTML 1708 views | ?
Chunhua Chen1,*, Xiangling Wang1,*, Juemin Fang2,*, Junli Xue3, Xunhao Xiong1, Yan Huang1, Jinghua Hu3 and Kun Ling1
1Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA
2Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
3Shanghai East Hospital, Tongji University, Shanghai, China
*These authors have contributed equally to this work
Kun Ling, email: email@example.com
Keywords: pancreatic cancer, type Iγ phosphatidylinositol phosphate kinase, EGFR, tyrosine phosphorylation, metastasis
Received: September 18, 2016 Accepted: January 24, 2017 Published: March 31, 2017
Pancreatic cancer is one of the deadliest malignancies and effective treatment has always been lacking. In current study, we investigated how the type Iγ phosphatidylinositol phosphate kinase (PIPKIγ) participates in the progression of pancreatic ductal adenocarcinoma (PDAC) for novel therapeutic potentials against this lethal disease. We found that PIPKIγ is up-regulated in all tested PDAC cell lines. The growth factor (including EGFR)-induced tyrosine phosphorylation of PIPKIγ is significantly elevated in in situ and metastatic PDAC tissues. Loss of PIPKIγ inhibits the aggressiveness of PDAC cells by restraining the activities of AKT and STAT3, as well as MT1-MMP expression. Therefore when planted into the pancreas of nude mice, PIPKIγ-depleted PDAC cells exhibits substantially repressed tumor growth and metastasis comparing to control PDAC cells. Results from further studies showed that the phosphorylation-deficient PIPKIγ mutant, unlike its wild-type counterpart, cannot rescue PDAC progression inhibited by PIPKIγ depletion. These findings indicate that PIPKIγ, functioning downstream of EGFR signaling, is critical to the progression of PDAC, and suggest that PIPKIγ is potentially a valuable therapeutic target for PDAC treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.